ACA
IONS icon

Aptus Capital Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Aptus Capital Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,450
Closed -$203K – 484
2020
Q2 		$203K Buy
+3,450
New +$192K 0.01% 260
2019
Q2 		– Sell
-2,576
Closed -$209K – 349
2019
Q1 		$209K Buy
+2,576
New +$166K 0.04% 297

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Aptus Capital Advisors's IONS Position: Q3 2020 in Review

Aptus Capital Advisors sold out of Ionis Pharmaceuticals (IONS) in Q3 2020, closing a stake of 3,450 shares — an estimated $203K sold.

Aptus Capital Advisors first reported a position in IONS in Q1 2019 and held it in 2 quarters. The position peaked at $209K in Q1 2019. 367 funds tracked by Wall St. Rank hold IONS as of Q3 2020.

  • Aptus Capital Advisors reported no remaining Ionis Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Aptus Capital Advisors sold 3,450 Ionis Pharmaceuticals shares in Q3 2020, an estimated $203K.
  • Aptus Capital Advisors first reported a position in Ionis Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Aptus Capital Advisors's Ionis Pharmaceuticals position peaked at $209K in Q1 2019.
  • 367 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2020.

Based on Aptus Capital Advisors's 13F filing for Q3 2020, filed 19 Oct 2020.